Market Place
Sourcing Support
SQZ opts for liquidation, $11.8M asset fire sale to Stemcell
01 Mar 2024 //
FIERCE BIOTECH
STEMCELL Technologies Announces Successful Asset Purchase Agreement with SQZ Bio
29 Feb 2024 //
BUSINESSWIRE
Ahead of shareholder vote on SQZ asset sale and liquidation
14 Feb 2024 //
ENDPTS
SQZ founder Armon Sharei opens Portal to cell engineering
12 Dec 2023 //
FIERCE BIOTECH
SQZ lays off 80% of staff, Regenxbio cuts 15%
09 Nov 2023 //
FIERCE BIOTECH
SQZ Biotechnologies Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
BUSINESSWIRE
SQZ Biotechnologies Reports Data for Clinical Programs
03 Nov 2023 //
BUSINESSWIRE
SQZ Biotechnologies Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
BUSINESSWIRE
Roche drops solid tumor option, intensifying the squeeze on SQZ
26 Jul 2023 //
FIERCE BIOTECH
SQZ Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient
22 Mar 2023 //
BUSINESSWIRE
SQZ Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate
06 Dec 2022 //
BUSINESSWIRE
SQZ, Synlogic pulled into biotech’s layoff sinkhole
01 Dec 2022 //
FIERCEBIOTECH
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen
30 Nov 2022 //
BUSINESSWIRE
SQZ Biotechnologies Reports 3Q 2022 Financial Results &Recent Portfolio Updates
09 Nov 2022 //
BUSINESSWIRE
SQZ Publishes Preclinical Research Demonstrating SQZ AAC Platform’s Potential
03 Oct 2022 //
BUSINESSWIRE
SQZ Biotechnologies to Present at Upcoming Investor Conferences
07 Sep 2022 //
BUSINESSWIRE
SQZ Biotechnologies Announces Leadership Transition
06 Sep 2022 //
BUSINESSWIRE
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ APCs
12 Jul 2022 //
BUSINESSWIRE
SQZ`s manufacturing method slashes production time in early in study
19 May 2022 //
ENDPTS
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies
05 May 2022 //
BUSINESSWIRE
SQZ Biotechnologies to Present at Upcoming Investor Conferences
03 May 2022 //
BUSINESSWIRE
SQZ Bio Receives FDA FTD for its Lead Cell Therapy Candidate for HPV16+ Tumors
27 Apr 2022 //
BUSINESSWIRE
SQZ Bio Presents New eAPC Preclinical Data on Multiplexed mRNA Engineering
11 Apr 2022 //
BUSINESSWIRE
SQZ Biotechnologies to Present at Upcoming Investor Conferences
06 Apr 2022 //
BUSINESSWIRE
SQZ Bio Publishes Comprehensive PC Research on SQZ TAC Platform’s Ability
04 Apr 2022 //
BUSINESSWIRE
SQZ Bio Reports FY 2021 Financial Results and Recent Portfolio Updates
16 Mar 2022 //
BUSINESSWIRE
SQZ Biotech to Present APC Platform Preclinical Findings and ENVOY-001 Trial
08 Mar 2022 //
BUSINESSWIRE
SQZ Biotechnologies Publishes Comprehensive Preclinical Research
01 Feb 2022 //
BUSINESSWIRE
FDA Clears SQZ Biotech`s IND for SQZ-eAPC-HPV in HPV16 Positive Solid Tumors
24 Jan 2022 //
BUSINESSWIRE
SQZ Biotechnologies Announces Acceptance by Roche Accelerator in China
01 Dec 2021 //
BUSINESSWIRE
SQZ Reports Q3 2021 Financial Results and Recent Portfolio Updates
10 Nov 2021 //
BUSINESSWIRE
SQZ Announces Independent DSMB Recommendation to Advance Lead Cell Therapy
26 Oct 2021 //
BUSINESSWIRE
SQZ Biotechnologies to Present at the Chardan 5th Genetic Medicines Conference
30 Sep 2021 //
BUSINESSWIRE
SQZ Announces First Autoimmune Disease Indication for TAC Platform
13 Sep 2021 //
BUSINESSWIRE
SQZ to Present First Clinical Data at the American Society of Clinical
18 May 2021 //
BUSINESSWIRE
SQZ to Present New Data on Rapid Cell Therapy Manufacturing Capabilities
27 Apr 2021 //
BUSINESSWIRE
SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing
27 Apr 2021 //
BUSINESSWIRE
SQZ Biotechnologies Reports 2020 Financial Results and Recent Advancements
18 Mar 2021 //
BUSINESSWIRE
SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow
01 Feb 2021 //
BUSINESSWIRE
SQZ Biotech Presents Preclinical Data for SQZ APC and AAC Cellular at SITC
10 Nov 2020 //
BUSINESSWIRE
SQZ Biotech & AskBio Announce Research Collab to Create Immune Tolerization
07 Nov 2019 //
PR NEWSWIRE
SQZ, Erytech kick off $57M cell therapy partnership
24 Jun 2019 //
ENDPTS
